Pharmacokinetics, distribution, metabolism and excretion of [3H]UCN-01 in rats and dogs after intravenous administration

被引:5
作者
Yasoshima, K [1 ]
Kuwabara, T [1 ]
Fuse, E [1 ]
Kuramitu, T [1 ]
Kurata, N [1 ]
Nishiie, H [1 ]
Oishi, T [1 ]
Kobayashi, H [1 ]
Kobayashi, S [1 ]
机构
[1] Kyowa Hakko Kogyo Co Ltd, Drug Dev Res Labs, Pharmaceut Res Inst, Nagaizumi, Shizuoka 4118731, Japan
关键词
7-hydroxystaurosporine (UCN-01); protein kinase inhibitor; metabolism; excretion; pharmacokinetics;
D O I
10.1007/s002800000213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pur pose: To evaluate the metabolic fate of UCN-01, a signal transduction inhibitor, blood and plasma concentrations, distribution, metabolism and excretion were investigated in rats and dogs after intravenous administration of [H-3]UCN-01. Methods: The radioactivity in plasma, blood and tissues was measured after intravenous administration of UCN-01. In addition, the radioactivity excreted in bile, urine and feces was also determined. Results: The radioactivity in rat and dog plasma disappeared triphasically with terminal half-lives of 21.3 and 27.2 h, respectively. The ratios of the blood-to-plasma concentrations ranged from 0.82 to 1.13 in rats and 0.81 to 1.73 in dogs. From 0.5 to 4 h after giving [H-3]UCN-01 to rats, the radioactivity in all tissues except the brain and testes was higher than in plasma. The highest concentration was observed in the lungs followed by the liver and kidneys. The radioactivity was mainly excreted in feces, reaching 96.0% of the radioactivity dose in rats and 78.4% in dogs up to 168 h after injection. Since the biliary excreted radioactivity was 67.2% over 48 h in bile duct-cannulated rats, most of the radioactivity excreted in feces was from biliary radioactivity. There were several metabolites in bile samples, but little UCN-01. Conclusions: UCN-01 is mainly eliminated by the liver, and there are high concentrations of radioactivity derived from [H-3]UCN-01 in all tissues except the brain and testes.
引用
收藏
页码:106 / 112
页数:7
相关论文
共 21 条
[1]   ENHANCEMENT OF ANTITUMOR-ACTIVITY OF MITOMYCIN-C INVITRO AND INVIVO BY UCN-01, A SELECTIVE INHIBITOR OF PROTEIN-KINASE-C [J].
AKINAGA, S ;
NOMURA, K ;
GOMI, K ;
OKABE, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (03) :183-189
[2]  
AKINAGA S, 1991, CANCER RES, V51, P4888
[3]  
AKINAGA S, 1993, P AM ASSOC CANC RES, V33, P3072
[4]  
Akiyama T, 1997, CANCER RES, V57, P1495
[5]  
Bunch RT, 1996, CLIN CANCER RES, V2, P791
[6]  
Fuse E, 1998, CANCER RES, V58, P3248
[7]  
Fuse E, 1999, CANCER RES, V59, P1054
[8]  
Gibaldi M., 1982, PHARMACOKINETICS, P409
[9]  
Harkin ST, 1998, MOL PHARMACOL, V54, P663
[10]   UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line [J].
Kawakami, K ;
Futami, H ;
Takahara, J ;
Yamaguchi, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 219 (03) :778-783